NCI Cancer Model Development for the Human Cancer Model Initiative
805 next-generation cancer models - organoids and other patient-derived systems - with whole genome sequencing on 804 and the matched patient tumor, spanning many rare cancers.
Can it answer your research question?
4 of 6 supportedOverall survival
SupportedVital status and time are populated; median follow-up 1.3 years; 544 cases with follow-up; endpoints: overall survival, progression-free interval.API
Progression or recurrence
SupportedA time to event is derivable: progression-free interval;
progression_or_recurrenceis informative for 65% of cases.APITreatment response
Supporteddisease_responseis populated for 61% of cases; criteria: complete response, cr-complete response.APIWhich drug was given
Supportedtherapeutic_agentsis recorded for 56% of cases.APIStage-adjusted modelling
Limitedajcc_pathologic_stageis informative for 41% of cases.APIAnalysis by race or ethnicity
LimitedRace is informative for 45% of cases.API
At a glance
Every percentage is the repository’s own record of what is filled inSubjectCALC
As filed by the repository
Who is in the cohortAPI
- Sex454 male · 351 female
- Race295 white · 38 black or african american · 30 asian · 1 1 other · 226 not reported · 215 unknown
- Ethnicity329 not hispanic or latino · 21 hispanic or latino · 231 unknown · 224 not reported
- Vital status290 alive · 187 dead · 299 not reported · 29 unknown
Age at diagnosis
What was measured, and on how many
- Clinical805 of 805 · 100%
- Whole genome sequencing804 of 805 · >99%
- Bulk RNA sequencing781 of 805 · 97%
- Whole exome sequencing721 of 805 · 90%
- DNA methylation array703 of 805 · 87%
- Copy Number Variation590 of 805 · 73%
- Somatic Structural Variation590 of 805 · 73%
- microRNA sequencing520 of 805 · 65%
- Whole-slide tissue images382 of 805 · 47%
- DICOM medical imaging382 of 805 · 47%
Platform, files and data levels
| Assay | Platform | Files | Levels |
|---|---|---|---|
| ClinicalAPI | - | 805 | - |
| Whole genome sequencingAPI | illumina | 11,357 | - |
| Bulk RNA sequencingAPI | illumina | 10,375 | - |
| Whole exome sequencingAPI | illumina | 14,470 | - |
| DNA methylation arrayAPI | illumina | 3,066 | - |
| Copy Number VariationAPI | - | 2,687 | - |
| Somatic Structural VariationAPI | - | 2,237 | - |
| microRNA sequencingAPI | illumina | 2,466 | - |
| Whole-slide tissue imagesAPI | illumina | 810 | - |
| DICOM medical imagingAPI | - | - | DICOM series |
How complete all 29 clinical fields are - 8 informative for at least 80% of cases
Outcome
Follow-up
Treatment
Diagnosis
Demographics
Access
Data Access Request through dbGaP using an eRA Commons account; institutional signing official approval required
- Open components
- 11,166 open-access files
- Controlled components
- 32,496 controlled-access files
- Typical turnaround
- days to a few weeks after signing official approval
- License
- NIH Genomic Data Sharing Policy terms
- Citation requirement
- Cite the dataset accession and the program's publication guidelines; see the GDC publication policy.
What it is good for
Written and checked by a reviewer, not generated from metadata.
1. How faithfully do patient-derived models retain the genomics of their source tumor?
Needs approved accessn ≈ 721HUMANModels and their source tumors are both characterized, with near-complete whole genome coverage, which makes fidelity measurable rather than assumed. The answer determines how much any model-based result should be trusted.
Statistical note: Verify model and source tumor pairing per case; it is not uniform.
NeedsWhole genome sequencingBulk RNA sequencingModel system2. Can a usable model system be found for a rare cancer that currently has none?
Answerable as shippedn ≈ 805HUMANCoverage spans many tumor types including rare ones. For a researcher working on a cancer with no established cell line, this is often the only route to any model at all, and it is the cohort's most practically valuable use.
Statistical note: Per-tumor-type counts are small; this is model discovery, not a powered comparison.
NeedsModel systemWhole genome sequencing3. Does prior treatment of the donor shape the derived model's biology?
Needs approved accessn ≈ 716HUMANPrior treatment is informative for 88.9% of donors and treatment given is recorded for all, so models derived from treated and untreated patients can be compared - a question with direct bearing on how model-based drug screens should be interpreted.
NeedsWhole genome sequencingBulk RNA sequencingTreatment recordsdiagnoses.prior_treatmentdiagnoses.treatments.treatment_type
What it cannot tell you
Written by a reviewer against the source, not inferred from what is missing.
Vital status is informative for 59.3% of cases and follow-up is derivable for 544 of 805. Progression and last known disease status are empty for all cases.
Affects: Survival analysis; Progression-free endpoints
Mitigation: Use the cohort for model characterization rather than for clinical outcome questions.
Race is not reported or unknown for 441 of 805 cases, over half the cohort, which undermines any claim that the model collection represents diverse populations.
Affects: Ancestry-aware model selection; Disparities research
Mitigation: Genetic ancestry can be estimated from the germline data, subject to consent terms.
These are model systems. Culture adaptation selects for growth-competent clones, so model genomics diverge from the source tumor over passage.
Affects: Direct clinical inference from model results
Mitigation: Record and report passage number; prefer early-passage models.
Spread across many tumor types, per-type counts are small.
Affects: Type-specific comparison
Mitigation: Treat as a model catalog rather than a cohort study.
A large share of the 43,662 files are controlled access.
Affects: Sequence-level analysis
Mitigation: Submit a dbGaP request.
Not appropriate for
- Survival analysis. - Vital status is informative for 59% of cases, and progression is absent entirely.HUMAN
- Treating model results as clinical evidence. - Models are experimental systems; translational claims require clinical validation this resource does not contain.HUMAN
Who has used it
Articles that analyzed these data, counted separately from articles that only cited the paper. Only the first counts as reuse.
What articles did with it
- Mentioned the dataset0
- Accession found in text6
- Declared using it1
- Analyzed the data6
Against comparable datasets
- Analyzed it6
- Expected~40
METHODS:"phs001486"), so every dataset in the corpus is counted the same way and the numbers can be compared. The 10 articles listed below were retrieved and graded one at a time, and an article counts as having analyzed the data wherever the accession sits in the analysis - methods, results, tables, figures or supplement - under any of this dataset’s accessions. Read the list as the evidence about these articles, and the count as the number that is comparable across datasets.- 6 article(s) reference this dataset's accession in a methods section, against 39.8 predicted for datasets of comparable size, age, modality breadth and access tier (reuse gap index -2.54 on a log2 scale, 4th percentile of the assessed corpus).
Articles that analyzed the data
- Data analyzedTEXT
Community examples
Share your exampleAnalyses someone ran on these data end to end, each with a receipt recording when it ran, against which packages and for how long.
Which cohorts have both imaging and molecular data on the same patients, and how many patients actually carry both?
Join the same patients across two NCI repositories
- Open GDC and IDC APIs, no account required
- pandas
- Patient-level intersection between a GDC project and an IDC collection
- Counts of molecular-only, imaging-only and joined patients
- A map of every cohort present in both repositories
- A chart comparing molecular and imaging patient counts per linkable cohort
Steps
- Retrieve patient identifiers from the GDC project
- Query IDC's public SQL endpoint for the collection's patient identifiers
- Intersect on the shared barcode and quantify the overlap
- Sweep every GDC project against every IDC collection
Start here
Starter code generated from this record’s own identifiers, then the access steps.
Get the data in code
GDC: list open files and download thempython
import json, requests
PROJECT = "HCMI-CMDC"
filters = {"op": "and", "content": [
{"op": "in", "content": {"field": "cases.project.project_id", "value": [PROJECT]}},
{"op": "in", "content": {"field": "access", "value": ["open"]}},
]}
params = {"filters": json.dumps(filters),
"fields": "file_id,file_name,data_category,data_type,file_size",
"size": "10000", "format": "JSON"}
files = requests.get("https://api.gdc.cancer.gov/files", params=params, timeout=60).json()["data"]["hits"]
print(len(files), "open files")
# Write a manifest and fetch with the GDC client (https://gdc.cancer.gov/access-data/gdc-data-transfer-tool)
with open("manifest.txt", "w") as fh:
fh.write("id\n" + "\n".join(f["file_id"] for f in files))
# $ gdc-client download -m manifest.txtGDC: clinical table for every casepython
import json, requests
filters = {"op": "in", "content": {"field": "project.project_id", "value": ["HCMI-CMDC"]}}
params = {"filters": json.dumps(filters), "size": "5000", "format": "TSV",
"fields": ",".join([
"submitter_id", "demographic.vital_status", "demographic.days_to_death",
"diagnoses.days_to_last_follow_up", "diagnoses.ajcc_pathologic_stage",
"diagnoses.treatments.treatment_type", "diagnoses.treatments.treatment_outcome"])}
tsv = requests.get("https://api.gdc.cancer.gov/cases", params=params, timeout=60).text
open("HCMI-CMDC_clinical.tsv", "w").write(tsv)IDC: pull the DICOM collection with idc-indexpython
from idc_index import IDCClient
COLLECTION = "hcmi_cmdc"
client = IDCClient()
series = client.index[client.index["collection_id"] == COLLECTION] # one row per DICOM series
print(len(series), "series,", series["PatientID"].nunique(), "patients,",
round(series["series_size_MB"].sum() / 1024, 1), "GB")
print(series["Modality"].value_counts().to_dict())
# Everything above is an index lookup and costs nothing. Uncomment to pull the pixels;
# the client refuses up front if the disk cannot hold them.
# client.download_from_selection(collection_id=COLLECTION, downloadDir="./hcmi_cmdc")This page as data: limitations firstbash
curl -s https://cd2s.vercel.app/data/datasets/gdc-hcmi-cmdc.json | python3 -c '
import json, sys
r = json.load(sys.stdin)
for l in r["limitations"]:
print(l["severity"].upper(), "-", l["statement"][:120])
print("survival endpoint:", r["longitudinal"]["has_survival_endpoint"], "| treatment response:", r["longitudinal"]["has_treatment_response"])'Access steps
- Search the model catalog for your tumor typeFor peoplehttps://portal.gdc.cancer.gov/projects/HCMI-CMDC
- Check model availability through the HCMI Searchable CatalogFor people
The data describe models; obtaining the physical model is a separate step.
https://ocg.cancer.gov/programs/HCMI - Submit a dbGaP data access request for sequence dataFor peoplehttps://gdc.cancer.gov/access-data/obtaining-access-controlled-data
- Query the project from code, with no credentialsFor agents
The file index is public even where files are not, so an agent can size the cohort before anyone requests access.
https://docs.gdc.cancer.gov/API/Users_Guide/Getting_Started/curl -s 'https://api.gdc.cancer.gov/files' --get \ --data-urlencode 'filters={"op":"in","content":{"field":"cases.project.project_id","value":["HCMI-CMDC"]}}' \ --data-urlencode 'fields=file_id,file_name,data_type' \ --data-urlencode 'size=10000' --data-urlencode 'format=TSV' - Pass the token when the agent needs controlled filesFor agents
Without a token, an API query may return only the open subset. Compare returned counts with the record before treating them as the whole cohort.
https://docs.gdc.cancer.gov/API/Users_Guide/Getting_Started/curl -H "X-Auth-Token: $GDC_TOKEN" https://api.gdc.cancer.gov/data/<file_id>
Provenance
All of it, and more, is in this record’s JSON.
Identifiers
Versions and verification
- Released
- 1 Jan 2022
- Metadata retrieved
- 18 Sept 2026
- Review status
- Project-curatedCD2S project curation on 18 Sept 2026
- Data generation funding
- Funded data generation
Funding
Funded reuse of these data
- R01CA292376Functional and molecular characterization of Oncofetal Stem Cells in CRCSlim MzoughiAPI
- R01CA272485Triggering a New Cancer Cell Death Mechanism in SarcomaScott DixonAPI
- K08CA230220Targeting casein kinase 1-alpha for cancer therapySteven Muntean CorselloAPI
Funded infrastructure or harmonization
- U01CA238475Predictive Modeling of the EGFR-MAPK pathway for Triple Negative Breast Cancer PatientsTimothy C Elston, CHARLES M PEROUAPI
- P50CA058223SPORE in Breast CancerLISA A CAREY, Gaorav P. GuptaAPI
- P30CA045508Cancer Research Training and Education Coordination CoreLloyd C Trotman, NICHOLAS K TONKSAPI
- P01CA013106Project 2: Splicing Dysregulation in CancerAdrian R Krainer, Camila dos SantosAPI
- P30CA196521The Tisch Cancer Institute - Cancer Center Support GrantRamon E Parsons, Nina BhardwajAPI
- P30CA124435Leadership, Planning and EvaluationSTEVEN E ARTANDI, MANISHA DESAIAPI